On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

420 with CNW – UK Doctors to Start Prescribing Cannabis in November

Doctors in the UK (Wales, Scotland and England) will soon start prescribing cannabis for their patients who have conditions that can be improved by this substance.

This announcement was made by the UK Home Secretary, Sajid Javid. He stated that cannabis would see its status changed from a schedule 1 substance (substances with no therapeutic value but having a high likelihood of being abused) to a schedule 2 controlled substance.

That change would allow doctors to prescribe cannabis-products for those patients who would benefit from such derivatives (CBD oil, for example).

However, cannabis would still be controlled since its new status would still regard it as something that has a high potential for being abused.

The Home Secretary said as much when he reiterated that adult use of cannabis would not be accepted and no patient would be allowed to smoke cannabis as a way of treating his or her condition.

The new regulations that will amend the Misuse of Drugs Regulations 2001 will come into force on November 1.

The amendments come hot on the heels of prominent cases in which several kids were denied the right to use cannabis oil as a way of controlling their epileptic seizures. Those cases were controversial because cannabis oil had been found to be beneficial for people suffering from refractory epilepsy.

The new regulations will permit three avenues through which a person can consume cannabis-based products. The first way is when the patient gets a prescription from a doctor to get a medical product made from cannabis.

The second way through which one can consume a cannabis product is when such a product is being used in an investigational program (clinical study) into which the user has been enrolled.

The third and final way through which one can consume a cannabis product is when such a product has been approved for sale by the relevant regulators. This category includes medicinal cannabis products that have been approved as over the counter products for which a prescription isn’t required.

The regulatory changes by the UK government comes at a time when an expert committee of the World Health Organization is set to meet in November to review the classification of marijuana as a schedule 1 controlled substance. That meeting also comes at a time when Canada has just made history as the first G8 member state to legalize recreational marijuana.

These positive actions in the cannabis industry are pieces of good news to Koios Beverage Corp. (CSE: KBEV) (OTC: KBEVF) and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) who are convinced about the benefits that this product can bring.

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

Archives

Select A Month

Official NewsWire Relationships

Alternative Products Expo Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo Cannabis World Congress & Business Exposition MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo

CannabisNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722